Department of Oncology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Department of Oncology, Chengdu BOE Hospital, Chengdu, Sichuan, China.
Front Immunol. 2024 Jun 14;15:1384111. doi: 10.3389/fimmu.2024.1384111. eCollection 2024.
Epithelioid hemangioendothelioma is a rare vascular malignancy, and currently, there is no standard treatment regimen for this disease and existing treatment options have limited efficacy. In this case report, we present a patient with lung and lymph node metastases from prostate epithelioid hemangioendothelioma who achieved a significant partial response. This was accomplished through alternating nivolumab therapy with ipilimumab and liposomal doxorubicin, resulting in a progression-free-survival more than 6 months to date. The treatment was well-tolerated throughout. Our report suggests that dual immunotherapy alternating with anti-PD-1antibody plus doxorubicin may be a potential treatment modality for epithelioid hemangioendothelioma. However, larger sample studies are necessary to ascertain the effectiveness of this treatment strategy and it is essential to continue monitoring this patient to sustain progression-free survival and overall survival.
上皮样血管内皮细胞瘤是一种罕见的血管恶性肿瘤，目前尚无针对这种疾病的标准治疗方案，现有的治疗选择疗效有限。在本病例报告中，我们报告了一例前列腺上皮样血管内皮细胞瘤肺和淋巴结转移的患者，该患者对治疗产生了显著的部分缓解。通过交替使用纳武单抗联合伊匹单抗和脂质体多柔比星治疗，达到了 6 个多月的无进展生存期。整个治疗过程中耐受性良好。我们的报告表明，抗 PD-1 抗体联合多柔比星的双免疫疗法可能是治疗上皮样血管内皮细胞瘤的一种潜在治疗方法。然而，需要更大样本的研究来确定这种治疗策略的有效性，并且必须继续监测该患者以维持无进展生存期和总生存期。
